TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02214290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: L-citrulline was used to examine the effect of the supplement on arterial function.
Study: NCT03400475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: One topical application in peri-implant gingival crevice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One topical application in peri-implant gingival crevice
Study: NCT03874572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose derived stem/stromal cells
Description: Culture expanded allogeneic adipose derived stem/stromal cells
Study: NCT00592904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
Study: NCT00921843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone 0.1mg/kg
Description: Subjects will receive methadone as their intraoperative opioid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methadone 0.2mg/kg
Description: Subjects will receive methadone as their intraoperative opioid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone 0.2mg/kg
Description: Subjects will receive methadone as their intraoperative opioid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone 0.3mg/kg
Description: Subjects will receive methadone as their intraoperative opioid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects will not receive methadone as their intraoperative opioid.
Study: NCT00398567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272
Description: HKI-272 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272
Description: HKI-272 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272
Description: HKI-272 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter
Study: NCT01961622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Florence D2A or similar closed loop glucose control system
Description: Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSII with real-time CGM
Description: Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
Study: NCT03189160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-rhGH low dose
Description: PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-rhGH low dose
Description: PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-rhGH high dose
Description: PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-rhGH high dose
Description: PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-treatment control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-treatment control group
Study: NCT01583855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation for atrial fibrillation, manual
Description: Ablation for atrial fibrillation will be performed manually

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation using Amigo remote catheter system
Description: Atrial fibrillation ablation will be performed using the Amigo remote catheter system
Study: NCT03504059

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Long-term educational program
Description: Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short-term educational program
Description: Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
Study: NCT03077581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transevrsus abdominus plane block
Description: a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectus sheath block
Description: In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia infiltartion
Description: 40 mls of 0.255 bupivacaine will be infiltrated at skin incision
Study: NCT02257502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
Study: NCT00660153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (AV-951) plus FOLFOX6
Description: Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15.
Study: NCT01338311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: 200mcg twice daily for a total of 7 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mcg twice a day for a total of 7 doses (3.5 days).
Study: NCT01476891

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate MBSR
Description: Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Control Group.
Description: Wait-list Control Group. The control group will receive the next available online MBSR program.
Study: NCT02340234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
Study: NCT00774774

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop
Study: NCT01156194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathy 1
Description: Arnica montana C6 and Bellis perennis C6
Study: NCT02340234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCS Cream
Description: TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCS Cream
Description: TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCS Cream
Description: TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCS Cream
Description: TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
Study: NCT01156194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathy 2
Description: Arnica montana C30 and Bellis perennis C30

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: globule identical to true homeopathy comparators
Study: NCT00774774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask
Description: Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~* during the night,~* when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended
Study: NCT00891709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102
Description: First-in-man. Healthy volunteers
Study: NCT00499603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Study: NCT00891709

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 29102
Description: First-in-man. Healthy volunteers
Study: NCT00348348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin
Description: Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin solution
Description: Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
Study: NCT00499603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Study: NCT01859689

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Undergo image-guided HDR brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Description: Undergo image-guided HDR brachytherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00058097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study: NCT03242239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT02

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-licensed Herceptin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Herceptin
Study: NCT04188457

Intervention type: OTHER
Intervention: Usual follow-up
Description: 2 medical consultations (nurse and doctor) over 24 months

Intervention type: OTHER
Intervention: Usual follow-up
Description: 2 medical consultations (nurse and doctor) over 24 months
Study: NCT00058097

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT01005810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: 1200 mg twice daily for 8 weeks
Study: NCT04188457

Intervention type: OTHER
Intervention: Intensive follow-up
Description: 10 medical visits (nurse, doctor, pharmacist) over 24 months
Study: NCT01005810

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 capsules twice daily for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
Study: NCT02952170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI to assess hepatic steatosis
Study: NCT01005810

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management
Description: rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
Study: NCT01103908

Intervention type: DEVICE
Intervention: HCE101 Cardiopulmonary Support Monitor
Description: Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
Study: NCT04176068

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)
Description: Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.
Study: NCT00984646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT01555892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells: A
Description: Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells: B
Description: Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
Study: NCT00984646

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT05771285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold application
Description: To evaluate the effect of cold application applied before subcutaneous low molecular weight heparin injection on post-injection pain, ecchymosis and hematoma formation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold application
Description: To evaluate the effect of cold application applied before subcutaneous low molecular weight heparin injection on post-injection pain, ecchymosis and hematoma formation.
Study: NCT02291705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectus sheath block
Description: ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: tramadol 1 mg/kg iv
Study: NCT01659697

Intervention type: BEHAVIORAL
Intervention: intensive lifestyle counseling
Description: Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise

Intervention type: BEHAVIORAL
Intervention: intensive lifestyle counseling
Description: Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
Study: NCT03486756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-CBT for anxiety-related asthma
Description: The specific assignments in the intervention will be based on individual behavior analysis for each participant.
Study: NCT04102605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nunap Vision
Description: Participants receive visual perceptual training using the Nunap Vision software

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nunap Vision-C
Description: Participants receive sham training using the Nunap Vision-C software
Study: NCT02464072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal Parathyroidectomy
Description: Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Parathyroidectomy + 45 autografts
Description: Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
Study: NCT00390338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: polarized dendritic cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-polarized dendritic cells
Study: NCT04056325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Monotherapy, oral administration, single dose, fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Monotherapy, oral administration, single dose, fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Monotherapy, oral administration, single dose, fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Monotherapy, oral administration, single dose, fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Monotherapy, oral administration, single dose, fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Monotherapy, oral administration, single dose, fixed dose
Study: NCT02464072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Parathyroidectomy + 90 autografts
Description: Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.